Pacer Advisors
NTLA icon

Pacer Advisors’s Intellia Therapeutics NTLA Stock Holding History

Pacer Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45K Buy
+2,665
New +$37.3K ﹤0.01% 2061
2024
Q3 		– Sell
-1,186
Closed -$26.5K – 2644
2024
Q2 		$26.5K Sell
1,186
-241
-17% -$5.74K ﹤0.01% 3374
2024
Q1 		$39.3K Buy
+1,427
New +$39.6K ﹤0.01% 3266
2021
Q2 		– Sell
-1,189
Closed -$95K – 1501
2021
Q1 		$95K Sell
1,189
-1,282
-52% -$86.1K ﹤0.01% 1302
2020
Q4 		$134K Sell
2,471
-208
-8% -$7.55K ﹤0.01% 1311
2020
Q3 		$53K Buy
+2,679
New +$55.9K ﹤0.01% 1303
2018
Q4 		– Sell
-7,558
Closed -$216K – 882
2018
Q3 		$216K Buy
+7,558
New +$220K 0.01% 1021

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Pacer Advisors's NTLA Position: Q2 2026 in Review

Pacer Advisors opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 2,665 shares worth $45K. The stake represents ﹤0.01% of the portfolio and ranks #2061 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in NTLA as recently as Q2 2024.

Pacer Advisors first reported a position in NTLA in Q3 2018 and has held it in 7 quarters since. The position peaked at $216K in Q3 2018. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Pacer Advisors held 2,665 shares of Intellia Therapeutics worth $45K as of Q2 2026.
  • Intellia Therapeutics was a new Pacer Advisors position in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2061 holding.
  • Pacer Advisors first reported a position in Intellia Therapeutics in Q3 2018 and has held it in 7 quarters since.
  • Pacer Advisors's Intellia Therapeutics position peaked at $216K in Q3 2018.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.